Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis.

ABSTRACT:

Background/aims

Perianal fistulas are a debilitating manifestation of Crohn's disease (CD). Despite the advent of anti-tumor necrosis factor (anti-TNF) therapy, the medical management of fistulizing CD continues to be challenged by unmet needs. We conducted a systematic review and meta-analysis of the effectiveness of vedolizumab for the management of perianal fistulizing CD.

Methods

A search of PubMed, EMBASE and the Cochrane Library was performed from inception to June 2020 for studies reporting rates of perianal fistula healing in CD patients treated with vedolizumab. The primary outcome of interest was complete healing of perianal fistulas and the secondary outcome was partial healing. The pooled fistula healing rates with 95% confidence intervals (CI) were calculated ut

SUBMITTER: Ayoub F 

PROVIDER: S-EPMC9081994 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature